J
Journey Medical Corporation (DERM)
NCM – Real Time Price. Currency in USD
6.62
+0.40 (6.43%)
At close: Jun 26, 2026, 4:00 PM EDT
6.41
-0.21 (-3.17%)
After-hours: Jun 26, 2026, 7:37 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
6.62
+0.40 (6.43%)
At close: Jun 26, 2026, 4:00 PM EDT
6.41
-0.21 (-3.17%)
After-hours: Jun 26, 2026, 7:37 PM EDT
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
| Name | Position |
|---|---|
| Dr. Lindsay Allan Rosenwald M.D. | Executive Chairman |
| Jaclyn Jaffe | Senior Director of Corporate Operations |
| Mr. Claude Maraoui | Founder, President, CEO & Director |
| Mr. Joseph M. Benesch | CFO & Corporate Controller |
| Mr. Louis Donati | Director of Market Access |
| Mr. Ramsey Alloush | COO, General Counsel & Company Secretary |
| Mr. Robert Nevin | Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-13 | 8-K | tm2614268d1_8k.htm |
| 2026-05-13 | 10-Q | derm-20260331x10q.htm |
| 2026-04-30 | DEF 14A | tm261508-3_def14a.htm |
| 2026-04-21 | 8-K | tm2612310d1_8k.htm |
| 2026-03-26 | 10-K | derm-20251231x10k.htm |
| 2026-03-25 | 8-K | tm269707d1_8k.htm |
| 2026-01-15 | S-3 | tm2534369d2_s3.htm |
| 2025-12-30 | DRS | filename1.htm |
| 2025-11-12 | 8-K | tm2530914d1_8k.htm |
| 2025-11-12 | 10-Q | derm-20250930x10q.htm |